Week in Review: Livzon Leads $26 Million Funding of Cynvenio

Livzon Pharma of Zuhai led a $26 million Series B funding of Cynvenio Biosystems, a Los Angeles diagnostics company; DelMar Pharma, a Canada-California drug company, will raise $8 million to develop its China-sourced cancer drug; J&J and WuXi AppTec will form a collaborative China life science incubator; China invalidated one of Gilead Sciences' patents for Sovaldi, its expensive new hepatitis C treatment; UCB of Belgium reported positive data from a China trial of its transdermal patch product for Parkinson's; Fosun Pharma said it would use M&A to increase ex-China revenues to 40% of sales; and Pfizer began construction of a $95 million production facility in Suzhou for consumer health products. More details.... Stock Symbols: (SZ: 000513 HK: 01513) (OTC: DMPI) (NYSE: JNJ) (NYSE: WX) (NSDQ: GILD) (EN: UCB) (SHA: 600196; HK: 2196) (NYSE: PFE) Share this with colleagues: // //